Clarus Wealth Advisors’s AbbVie ABBV Stock Holding History

Clarus Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.3M	Buy	9,101 +1,417	+18%	+$305K	0.89%	41
2026 Q1	$1.59M	Buy	+7,684	New	+$1.7M	0.68%	52
2024 Q1	–	Sell	-1,328	Closed	-$217K	–	131
2023 Q4	$217K	Buy	+1,328	New	+$194K	0.13%	109
2023 Q1	–	Sell	-1,266	Closed	-$202K	–	126
2022 Q4	$202K	Sell	1,266 -264	-17%	-$40.5K	0.13%	114
2022 Q3	$212K	Buy	+1,530	New	+$220K	0.15%	104
2022 Q2	–	Sell	-1,246	Closed	-$212K	–	99
2022 Q1	$212K	Buy	+1,246	New	+$181K	0.13%	101
2020 Q3	–	Sell	-3,418	Closed	-$340K	–	125
2020 Q2	$340K	Buy	3,418 +200	+6%	+$17.6K	0.29%	76
2020 Q1	$236K	Buy	+3,218	New	+$274K	0.24%	102
2019 Q3	–	Sell	-1,758	Closed	-$128K	–	148
2019 Q2	$128K	Buy	1,758 +15	+0.9%	+$1.18K	0.09%	159
2019 Q1	$140K	Sell	1,743 -7	-0.4%	-$573	0.1%	148
2018 Q4	$161K	Buy	1,750 +18	+1%	+$1.58K	0.25%	107
2018 Q3	$164K	Sell	1,732 -914	-35%	-$86.7K	0.11%	158
2018 Q2	$250K	Hold	2,646	–	–	0.19%	77
2018 Q1	$250K	Sell	2,646 -3,238	-55%	-$356K	0.23%	77
2017 Q4	$569K	Buy	+5,884	New	+$555K	0.55%	26

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Clarus Wealth Advisors's ABBV Position: Q2 2026 in Review

Clarus Wealth Advisors increased its AbbVie (ABBV) stake by 18% in Q2 2026, buying an estimated $305K and bringing the position to 9,101 shares worth $2.3M. The position accounts for 0.89% of the portfolio, ranked #41.

Clarus Wealth Advisors first reported a position in ABBV in Q4 2017 and has held it in 15 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Clarus Wealth Advisors held 9,101 shares of AbbVie worth $2.3M as of Q2 2026.
Clarus Wealth Advisors bought 1,417 AbbVie shares in Q2 2026, an estimated $305K.
AbbVie made up 0.89% of Clarus Wealth Advisors's portfolio in Q2 2026, its #41 holding.
Clarus Wealth Advisors first reported a position in AbbVie in Q4 2017 and has held it in 15 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Clarus Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.